Lymphoma, Leukemia Patients Sought for Trial of MoAb

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

BOSTON--Researchers at New England Deaconess Hospital are seeking patients with Hodgkin's disease, non-Hodgkin's lymphoma, acute myelogenous leukemia (AML), and chronic myelogenous leukemia (CML) for an FDA-sponsored study of a humanized anti-Tac (interleukin-2 receptor) monoclonal antibody. The phase Ib/II multidose trial will study tolerance, therapeutic efficacy, and biological efficacy.

BOSTON--Researchers at New England Deaconess Hospital are seekingpatients with Hodgkin's disease, non-Hodgkin's lymphoma, acutemyelogenous leukemia (AML), and chronic myelogenous leukemia (CML)for an FDA-sponsored study of a humanized anti-Tac (interleukin-2receptor) monoclonal antibody. The phase Ib/II multidose trialwill study tolerance, therapeutic efficacy, and biological efficacy.

The protocol (92-0205-34) calls for patients over the age of 18with a life expectancy greater than 2 months and confirmed Tacon malignant cells, except for Hodgkin's disease patients, forwhich all R-S (Reed-Sternberg) cells are Tac-positive. Also, patientsmust be able to have continuous local access for 1 month.

Hodgkin's disease patients (25 to be enrolled) must have failedfirst-line therapy and one salvage attempt. Non-Hodgkin's lymphomapatients with aggressive disease must have failed first-line therapy;if indolent, any patient is eligible. All CML patients (eightto be enrolled) are eligible. AML patients (eight to be enrolled)must have failed first-line therapy or be in first or later relapse.

For more information, contact Dan Hagg, New England DeaconessHospital, 21-27 Burlington Avenue, 5th Floor, Boston, MA 02215.Phone: 617-632-0316.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Related Content